600-57-7

Basic information

• Product Name: 11BETA-HYDROXYPROGESTERONE
• Synonyms: 11-beta-hydroxy-pregn-4-ene-20-dione;11-beta-hydroxypregn-4-ene-3,20-dione;11-hydroxy-20-dion(11-beta)-pregn-4-ene-;21-deoxycorticosterone;HYDROXYPROGESTERONE, 11B-;4-PREGNEN-11BETA-3,20-DIONE;4-PREGNEN-11BETA-OL-3,20-DIONE;11B-HYDROXYPROGESTERONE
• CAS NO: 600-57-7
• Molecular Formula: C21H30O3
• Molecular Weight: 330.46
• EINECS: 209-995-8
• Product Categories: Steroids
• Mol File: 600-57-7.mol
• Article Data: 7

Chemical Properties

• Melting Point: 181～184℃
• Boiling Point: 487.4 °C at 760 mmHg
• Flash Point: 262.7 °C
• Appearance: /
• Density: 1.15 g/cm³
• Vapor Pressure: 1.51E-11mmHg at 25°C
• Refractive Index: 1.557
• Storage Temp.: 2-8°C
• Solubility: Acetone (Slightly), Chloroform (Slightly), Methanol (Slightly)
• PKA: 14.52±0.70(Predicted)
• Water Solubility: 30.84mg/L(37 oC)
• CAS DataBase Reference: 11BETA-HYDROXYPROGESTERONE(CAS DataBase Reference)
• NIST Chemistry Reference: 11BETA-HYDROXYPROGESTERONE(600-57-7)
• EPA Substance Registry System: 11BETA-HYDROXYPROGESTERONE(600-57-7)

Safety Data

• Hazardous Substances Data: 600-57-7(Hazardous Substances Data)

Usage

Uses

11β-Hydroxy Progesterone is a derivative of Progesterone (P755900) is a steroid hormone produced by the corpus luteum. Induces maturation and secretory activity of the uterine endothelium; suppresses ovulation. Progesterone is implicated in the etiology of breast cancer.This compound is a contaminant of emerging concern (CECs).

InChI:InChI=1/C21H30O3/c1-12(22)16-6-7-17-15-5-4-13-10-14(23)8-9-20(13,2)19(15)18(24)11-21(16,17)3/h10,15-19,24H,4-9,11H2,1-3H3

Upstream product

• 110-86-1 pyridine 
• 67-66-3 chloroform 
• 50-22-6 Corticosterone 
• 98-59-9 p-toluenesulfonyl chloride 
• 2302-12-7 17-acetyl-10,13-dimethyl-1,6,7,8,9,10,12,13,14,15,16,17-dodecahydro-2H-cyclopenta[a]phenanthrene-3,11-dione-3,21-diethylene ketal 
• 80-75-1 11-alpha-hydroxyprogesterone 
• 3754-67-4 (8S,9S,10S,11S,13S,14S,17S)-10,13-dimethyl-17-(2-methyl-1,3-dioxolan-2-yl)hexadecahydrospiro[cyclopenta[a]phenanthrene-3,2′-[1,3]dioxolan]-11-ol 
• 55561-02-9 thiopivalic acid 
• 57524-89-7 hydrocortisone valerate 
• 15807-40-6 20,20-ethanediyldioxy-5β-pregnane-3α,11β-diol 
• 55176-88-0 11β-hydroxy-5β-pregnane-3,20-dione 
• 565-92-4 5β-pregnan-3α,11β-diol-20-one 
• 58761-31-2 Pregn-4-en-3,11,20-trion-3,20-bis-semicarbazon 
• 516-15-4 11-Ketoprogesterone 

Downstream Products

• 566-65-4 dihydroprogesterone 
• 17652-16-3 pregna-4,9⁽¹¹⁾-diene-3,20-dione 
• 516-15-4 11-Ketoprogesterone 
• 4224-37-7 11β-hydroxypregna-1,4-diene-3,20-dione 

Relevant articles and documents

Dehalogenation methodof 9-halogenated steroid compound and application

The invention provides a dehalogenation method of a 9-halogenated steroid compound and application, and relates to the technical field of chemical synthesis. The dehalogenation method of the 9-halogenated steroid compound comprises the following steps: reacting a compound I with a hydrogen donor and an azo radical initiator to obtain a 9-dehalogenated product compound II of the 9-halogenated steroid compound. According to the dehalogenation method of the 9-halogenated steroid compound, a hydrogen donor adopts one or a combination of more of hypophosphorous acid and hypophosphite, formic acid and formate, organic silicon hydride, hydrazine compounds or cyclohexene, and an initiator adopts an azo free radical initiator. Reagents such as chromium, divalent chromium salt, trivalent chromium salt or tributyltin hydride which are high in toxicity and cause serious pollution to the environment are not used in the reaction, the method is green and environmentally friendly, the synthesis process is simple, convenient and easy to implement, and the production applicability is improved.

Raw synthesis and mitochondrial function postischemic mitochondria diseases related to the lack or for use in new compd. 11β-hydroxysteroid

The present invention provides novel compounds of 112-hydroxy steroids and compositions and their application as pharmaceuticals for preventing or reversing injury to mitochondria, for treating or preventing diseases relating to mitochondrial dysfunction or depletion, and for inducing regeneration or restructuring of mitochondria as a means of treating diseases relating to abnormalities in mitochondrial structure and function in a human or animal subject. Also disclosed herein are methods for diagnosing injury to mitochondria and for diagnosing the success or failure of therapeutics designed to treat, prevent, or reverse injury to or depletion of mitochondria.

Steroids esterified in position 17 and thioesterified in position 21, a process for preparing them and their use as medicaments

Compounds of formula: STR1 wherein A and B each represent, independently of each other, a straight-chained or branched alkyl group having from 1 to 6 carbon atoms or a phenyl group optionally mono- or polysubstituted by alkyl radicals having from 1 to 6 carbon atoms, alkoxy groups having from 1 to 6 carbon atoms or halogen, T and U, independently of each other, represent hydrogen atoms or together form a double bond, V is a hydrogen atom or a methyl group at the α-position, W is a hydrogen atom or a halogen atom at the α-position, X is a hydroxy group at the β-position and Y is a hydrogen atom or X and Y may together represent an oxygen atom, and Z1 is a hydrogen atom, a methyl group at the α- or β-position, while Z2 is a hydrogen atom, or Z1 and Z2 together form a methylene group. These compounds have anti-inflammatory activity.